ClinicalTrials.gg
CompletedNCT03228836ORIENT-4Updated Jan 12, 2021Results posted

Efficacy and Safety Evaluation of IBI308 in Patients With Extranodal NK/T Cell Lymphoma Patients

A Phase 2 interventional study of Sintilimab in Effect of Drugs, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-01-12.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This is phase II study. Efficacy and safety evaluation of IBI308 in patients with relapsed/refractory extranodal NK/T cell lymphoma, nasal type: a multicenter, single arm.

Read the detailed description

Extranodal NK/T cell lymphoma, nasal type(ENKTL) accounts for about 6% of all lymphomas in china. Epstein Barr virus (EBV) infection is found in all cases of ENKTL and maybe plays an important pathogenetic role.

Conventional anthrocycline-based regimens are not preferred to be used in ENKTL because of high p-glycoprotein expression. ORR of L-asparaginase based regimens is about 80% and no salvage regimens are recommended in ENKTL so far after failure of L-asparaginase based regimen.

Recently, a phase II clinical trial result demonstrated high ORR of anti-PD-1 antibody treatment in ENKTL.IBI308, a humanized monoclonal antibody (mAb) directly against PD-1, is investigated in this phase II Chinese ENKTL clinical trial.

Additionally the correlation between PD-L1 expression and the response to IBI308 treatment in Chinese ENKTL subjects will also be assessed.

02

Conditions studied

  • Effect of Drugs
03

In context

Lead sponsor

Innovent Biologics (Suzhou) Co. Ltd. is the lead sponsor of 199 studies on the registry; 46 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Inclusion Criteria

  1. confirmed ENKL-NT.
  2. ENKTL-NT. Being relapsed is defined as presence of new lesions at the primary location or other sites after achieving CR; being refractory is defined as any one of the followings: PD after 2 treatment cycles, PR not achieved after 4 treatment cycles, or CR not achieved after 6 treatment cycles. Patients who do not response or patients with relapsed disease or PD after stem cell transplantation can enroll.
  3. Must have been treated with asparaginase-based regimen (radiotherapy must be performed for stage I/II disease).
  4. Long axis of a lesion > 15 mm or 18FDG-PET uptake by lesion.
  5. Performance Status (ECOG PS) scores of 0-2.
  6. Signed the inform consent form (ICF) and able to comply with the scheduled follow-up visits and related procedures required in the protocol.
  7. Between the ages of ≥18 to ≤70 years.
  8. ≥ 12 weeks.
  9. Patients (female patients at childbearing age or male patients whose partners are at childbearing age) must take effective measures during the entire course of the trial and within 90 days since the last dose of treatment.
  10. Adequate organs and bone marrow functions, as defined below: Count of whole blood cells: (ANC) ≥1.0×10\^9/L, (PLTs) count ≥ 50×10\^9/L, (HGB) ≥ 8.0 g/L; granulocyte colony-stimulating factor, PLT, or red blood cell (RBC) transfusion has not been performed within 7 days prior to the test. Hepatic function: total (TBIL) ≤ 1.5× (ULN), (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN. Renal function:serum creatinine (Cr) ≤ 1.5 × ULN. Thyroid function: normal thyroid stimulating hormone (TSH) at baseline, or abnormal TSH at baseline with normal thiiodothronine (T3)/thiiodothronine (T4) and no symptoms.

Exclusion Criteria:

  1. Patients with aggressive NK cell leukemia.
  2. Patients with primary or secondary central nervous system (CNS) lymphoma.
  3. Patients with severe hemophagocytic syndrome at initial diagnosis of ENKTL-NT.
  4. Patients with pulmonary great vessel invasion.
  5. Previous exposure to any , anti-PD-L1, or anti-CTLA-4 antibodies.
  6. Enrolled in another interventional clinical study, unless only involved in an observational study (non-interventional) or in the follow-up phase of an interventional study.
  7. Received any drug within 4 weeks prior to the first dose of study treatment.
  8. The last dose of radiation or anti-tumor therapy (chemotherapy, targeted therapy or tumor embolization) was within 3 weeks prior to receiving the first dose of study treatment; the last dose of nitrosourea or mitomycin C treatment was within 6 weeks prior to receiving the first dose of study treatment.
  9. Received within 4 weeks prior to the first dose of study treatment, excluding local administered by nasal, inhaled, or other topical routes, or systemic glucocorticoids of physiological doses (no more than 10 mg/day of prednisone or equivalents).
  10. Received any within 4 weeks prior to the first dose of study treatment, or is scheduled to receive live attenuated vaccine during the study period.
  11. Received major surgery (craniotomy, thoracotomy, or laparotomy) within 4 weeks prior to the first dose of study treatment, or has unhealed wounds, ulcers, or fractures.
  12. Active, known, or suspected disease (see Appendix 6) or previous medical history of these diseases within 2 years (patients with vitiligo, psoriasis, alopecia, or Graves' disease not requiring systemic treatment, hypothyroidism only requiring thyroid replacement, or type I diabetes only requiring insulin can enroll).
  13. Known history of primary immunodeficiency diseases.
  14. Known active pulmonary tuberculosis.
  15. Known history of allogeneic organ transplantation or allogeneic hem atopoietic stem cell transplantation.
  16. Known to be allergic to any ingredients of monoclonal antibodies.
  17. Uncontrolled concurrent diseases including but not limited to:

    -infected patients (positive anti-HIV antibody). Active or poorly controlled severe infections. Symptomatic congestive heart failure ( Class III-IV) or symptomatic or poorly controlled arrhythmia.

    Uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg) despite of standard treatment.

    Any arterial thromboembolic events occurred within 6 months prior to enrollment, including myocardial infarction, unstable angina, cerebrovascular accident, or transient cerebral ischemic attack.

    Life-threatening hemorrhagic events or grade 3-4 gastrointestinal/variceal hemorrhage requiring blood transfusion, endoscopy, or surgical treatment within 3 months prior to enrollment.

    History of deep venous thrombosis, pulmonary embolism, or other serious thromboembolic events within 3 months prior to enrollment (implantable port or catheter-related thrombosis, or superficial venous thrombosis are not considered as serious thromboembolisms).

    Uncontrolled metabolic disorders, non-malignant organ or systemic diseases, or cancer-related secondary diseases that may lead to higher medical risks and/or survival evaluation uncertainties.

    Hepatic encephalopathy, hepatorenal syndrome, or cirrhosis with grade B or C.

    Bowel obstruction or history of the following diseases: inflammatory bowel disease or extensive bowel resection (partial colectomy or extensive small bowel resection accompanied with chronic diarrhea), Crohn's disease, and ulcerative colitis.

    Acute or chronic diseases, psychiatric disorders, or laboratory abnormalities that may lead to the following consequences: increased investigational drug-related risks, or interference with interpreting trial results, and considered ineligible for participating in the trial by the investigators.

  18. Known acute or chronic active (chronic HBV carriers or inactive HBsAg-positive patients can enroll if the HBV DNA \< 1×10\^3 copies/mL), or acute or chronic active (patients with negative HCV antibody can enroll; HCV RNA test is required for patients with positive HCV antibody, those test negative can enroll).
  19. History of GI perforation and/or fistula without radical treatment within 6 months prior to the enrollment.
  20. Known interstitial lung disease.
  21. Clinically uncontrollable third spacing, such as pleural effusion and ascites that cannot be controlled by drainage or other methods prior to enrollment.
  22. History of other primary malignant tumors, excluding:

    History of radical treatment for malignant tumors with no evidence of tumor recurrence for more than 5 years prior to enrollment and with a very low risk of recurrence.

    Adequately treated nonmelanoma skin cancer or lentigo maligna with no signs of disease recurrence.

    Adequately treated carcinoma in situ with no signs of disease recurrence.

  23. Pregnant or breastfeeding female patients.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Sintilimab (IBI308)

    Drug: Sintilimab

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) Before First PD

    The tumor assessment is according to Lugano 2014 Criteria and then International Working Group (IWG) 2007 Criteria after 24 weeks. Objective response is defined as best overall response (CR or PR) across all assessment time points during the period from enrollment to termination of trial treatment (per Lugano 2014 criteria during intial 24 weeks, per IWG 2007 criteria after 24 weeks). The primary efficacy endpoint is ORR evaluated using the 2014 Lugano Criteria before first progression disease (PD).

    Time frame: Up to ~30 months (through database cut-off date of 28-February-2020)

Secondary outcomes

  1. Progression Free Survival (PFS)

    PFS was defined as the time from the first dose to the first documented progressive disease (PD) per Lugano 2014 or death due to any cause, whichever occurred first. Participates who neither progress nor die were censored at the date of their last tumor imaging evaluation. Participates who did not have any tumor imaging evaluation after baseline were censored on the date of enrollment.

    Time frame: Up to ~30 months (through database cut-off date of 28-February-2020)

  2. Duration of Response (DOR)

    DOR was defined as the time from first date of response to first PD per Lugano 2014 or death. Subjects who neither progress nor die were censored at the date of their last tumor imaging evaluation.

    Time frame: Up to ~30 months (through database cut-off date of 28-February-2020)

07

Results

Posted Dec 17, 2020

Participant flow

Participant flow — Overall Study
MilestoneSintilimab (IBI308)
Started28
Treated28
Completed11
Not completed17
Withdrew: Adverse event3
Withdrew: Withdrawal by subject1
Withdrew: Death1
Withdrew: Physician decision1
Withdrew: Disease progression7
Withdrew: Other4

Outcome measures

PrimaryObjective Response Rate (ORR) Before First PD

The tumor assessment is according to Lugano 2014 Criteria and then International Working Group (IWG) 2007 Criteria after 24 weeks. Objective response is defined as best overall response (CR or PR) across all assessment time points during the period from enrollment to termination of trial treatment (per Lugano 2014 criteria during intial 24 weeks, per IWG 2007 criteria after 24 weeks). The primary efficacy endpoint is ORR evaluated using the 2014 Lugano Criteria before first progression disease (PD).

Time frame:
Up to ~30 months (through database cut-off date of 28-February-2020)
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) Before First PD
Percentage of ParticipantsSintilimab (IBI308)
Objective Response Rate (ORR) Before First PD60.7 (40.6 to 78.5)
SecondaryProgression Free Survival (PFS)

PFS was defined as the time from the first dose to the first documented progressive disease (PD) per Lugano 2014 or death due to any cause, whichever occurred first. Participates who neither progress nor die were censored at the date of their last tumor imaging evaluation. Participates who did not have any tumor imaging evaluation after baseline were censored on the date of enrollment.

Time frame:
Up to ~30 months (through database cut-off date of 28-February-2020)
Reported as:
Median · Days
Progression Free Survival (PFS)
DaysSintilimab (IBI308)
Progression Free Survival (PFS)104.0 (45.0 to 419.0)
SecondaryDuration of Response (DOR)

DOR was defined as the time from first date of response to first PD per Lugano 2014 or death. Subjects who neither progress nor die were censored at the date of their last tumor imaging evaluation.

Time frame:
Up to ~30 months (through database cut-off date of 28-February-2020)
Reported as:
Median · Days
Duration of Response (DOR)
DaysSintilimab (IBI308)
Duration of Response (DOR)126.0 (64.0 to 463.0)

Adverse events

Collected over Up to ~30 months (through database cut-off date of 28-February-2020). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sintilimab (IBI308)7/28 (25%)7/28 (25%)28/28 (100%)
Most frequent serious events
Most frequent serious events
EventSintilimab (IBI308)
Gastrointestinal haemorrhageGastrointestinal disorders1/28
Pancreatitis acuteGastrointestinal disorders1/28
Disease progressionGeneral disorders1/28
PyrexiaGeneral disorders1/28
Anaphylactic shockImmune system disorders1/28
Localised infectionInfections and infestations1/28
PneumoniaInfections and infestations1/28
Diabetic ketoacidosisMetabolism and nutrition disorders1/28
Intervertebral disc disorderMusculoskeletal and connective tissue disorders1/28
Most frequent other events
Showing 10 of 61
Most frequent other events
EventSintilimab (IBI308)
Lymphocyte count decreasedInvestigations17/28
White blood cell count decreasedInvestigations14/28
PyrexiaGeneral disorders13/28
HypothyroidismEndocrine disorders9/28
Haemoglobin decreasedInvestigations9/28
Blood thyroid stimulating hormone increasedInvestigations8/28
Upper respiratory tract infectionInfections and infestations7/28
Blood glucose increasedInvestigations7/28
Blood alkaline phosphatase increasedInvestigations6/28
Blood lactate dehydrogenase increasedInvestigations6/28

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Sintilimab (IBI308)
<=18 years0
Between 18 and 65 years27
>=65 years1
Age, Continuous
Age, Continuous(years)Sintilimab (IBI308)
Mean40.32 ± 12.67
Sex: Female, Male
Sex: Female, Male(Participants)Sintilimab (IBI308)
Female11
Male17
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sintilimab (IBI308)
American Indian or Alaska Native0
Asian28
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Sintilimab (IBI308)
China28
08

Study locations

1 site
  • Jiangsu Provincial Hospital
    Nanjing, Jiangsu, China
09

References and documents

Publications

  • Tao R, Fan L, Song Y, Hu Y, Zhang W, Wang Y, Xu W, Li J. Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4). Signal Transduct Target Ther. 2021 Oct 27;6(1):365. doi: 10.1038/s41392-021-00768-0. PubMed 34702811 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2017 to primary completion in Feb 2020, 30 months.

Results were first posted in Dec 2020, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2017
First posted
Jul 25, 2017
StartActual
Aug 23, 2017
Primary completionActual
Feb 28, 2020
CompletionActual
Feb 28, 2020
Results first posted
Dec 17, 2020
Last update
Jan 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03228836
Responsible party
Sponsor
First posted
Jul 25, 2017
Start date
Aug 23, 2017
Primary completion
Feb 28, 2020
Completion
Feb 28, 2020
Results posted
Dec 17, 2020
Last update
Jan 12, 2021

Study contacts

Jian-yong Li, Master
principal investigator · The First Affiliated Hospital with Nanjing Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sintilimab

Start the discussion